Jefferies Maintains Buy on Ascendis Pharma, Raises Price Target to $196
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Kelly Shi maintains a Buy rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $174 to $196.
August 13, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analyst Kelly Shi maintains a Buy rating on Ascendis Pharma and raises the price target from $174 to $196.
The raised price target and maintained Buy rating from a reputable analyst at Jefferies is likely to positively impact investor sentiment and drive short-term price appreciation for Ascendis Pharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100